Bank of New York Mellon
FDMT icon

Bank of New York Mellon’s 4D Molecular Therapeutics FDMT Stock Holding History

Bank of New York Mellon’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Buy
152,337
+18,730
+14% +$182K ﹤0.01% 2940
2026
Q1 		$1.24M Sell
133,607
-3,132
-2% -$27.3K ﹤0.01% 3081
2025
Q4 		$1.03M Sell
136,739
-4,977
-4% -$50.5K ﹤0.01% 3218
2025
Q3 		$1.23M Buy
141,716
+616
+0.4% +$3.68K ﹤0.01% 3087
2025
Q2 		$523K Buy
141,100
+6,251
+5% +$22K ﹤0.01% 3485
2025
Q1 		$436K Sell
134,849
-11,092
-8% -$52.3K ﹤0.01% 3518
2024
Q4 		$813K Sell
145,941
-464
-0.3% -$3.64K ﹤0.01% 3276
2024
Q3 		$1.58M Sell
146,405
-23,008
-14% -$382K ﹤0.01% 2866
2024
Q2 		$3.56M Buy
169,413
+38,015
+29% +$954K ﹤0.01% 2499
2024
Q1 		$4.19M Sell
131,398
-13,542
-9% -$345K ﹤0.01% 2404
2023
Q4 		$2.94M Buy
144,940
+9,229
+7% +$121K ﹤0.01% 2636
2023
Q3 		$1.73M Buy
135,711
+19,434
+17% +$325K ﹤0.01% 2893
2023
Q2 		$2.1M Buy
116,277
+7,822
+7% +$144K ﹤0.01% 2802
2023
Q1 		$1.86M Sell
108,455
-1,455
-1% -$28.3K ﹤0.01% 2841
2022
Q4 		$2.44M Buy
109,910
+2,693
+3% +$41.6K ﹤0.01% 2740
2022
Q3 		$862K Buy
107,217
+9,410
+10% +$85.2K ﹤0.01% 3279
2022
Q2 		$682K Sell
97,807
-3,515
-3% -$34.2K ﹤0.01% 3410
2022
Q1 		$1.53M Buy
101,322
+1,136
+1% +$17.8K ﹤0.01% 3078
2021
Q4 		$2.2M Buy
100,186
+30,968
+45% +$759K ﹤0.01% 2934
2021
Q3 		$1.87M Buy
69,218
+40,582
+142% +$1.16M ﹤0.01% 3017
2021
Q2 		$689K Buy
28,636
+8,219
+40% +$252K ﹤0.01% 3622
2021
Q1 		$885K Buy
+20,417
New +$904K ﹤0.01% 3401

Other funds holding FDMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of New York Mellon's FDMT Position: Q2 2026 in Review

Bank of New York Mellon increased its 4D Molecular Therapeutics (FDMT) stake by 14% in Q2 2026, buying an estimated $182K and bringing the position to 152,337 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

Bank of New York Mellon first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.19M in Q1 2024. 54 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Bank of New York Mellon held 152,337 shares of 4D Molecular Therapeutics worth $2.03M as of Q2 2026.
  • Bank of New York Mellon bought 18,730 4D Molecular Therapeutics shares in Q2 2026, an estimated $182K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2940 holding.
  • Bank of New York Mellon first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Bank of New York Mellon's 4D Molecular Therapeutics position peaked at $4.19M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.